This was well demonstrated in a trial where participants taking semaglutide 2.4 mg weekly for weight loss regained two-thirds of their prior weight loss within a year of stopping the medication
In theory, targeting two different metabolic pathways could provide a synergistic effect
"The BALANCE Model and a New Wave of CMS Drug Pricing Models." BALANCE waives Part D weight-loss exclusion
If you pay for the program upfront and your insurance subsequently denies the medication, Calibrate's refund policies are highly restrictive, making it an extremely high-risk option for uninsured patients
Acknowledgements The authors would like to acknowledge the use of artificial intelligence tools, such as ChatGPT, for assisting in literature search
Purohit TJ, Hanning SM, Wu Z (2018) Advances in rectal drug delivery systems